Scientists Are Engineering Immune 'Bodyguards' to Finally Cure Type 1 Diabetes

For millions of people with type 1 diabetes, life is an unrelenting negotiation with their own immune system. The condition is not a failure of the pancreas. It is an attack on it. In type 1 diabetes, the body's immune system mistakenly identifies the insulin-producing beta cells as a threat, and destroys them. Without those cells, blood sugar goes unregulated. Without daily insulin injections, the condition is fatal. And despite a century of medical progress, a true cure has remained stubbornly out of reach. Now, a team at the Medical University of South Carolina — backed by a $1 million award from Breakthrough T1D, the world's leading type 1 diabetes research organisation — is attempting something that sounds almost impossibly elegant: training the immune system to protect the very cells it has been destroying. The approach, led by immunologist Dr. Leonardo Ferreira, centres on a type of immune cell called a regulatory T cell, or Treg. Tregs are the body's peacekeepers — cells whose job is to prevent immune overreaction and protect healthy tissue. In type 1 diabetes, those peacekeepers have failed to defend the beta cells. Ferreira's strategy is to engineer them so they don't fail again. Using chimeric antigen receptors — the same technology that has transformed cancer treatment through CAR-T cell therapy — the team is building Tregs with customised targeting receptors that direct them specifically to the pancreatic environment. Once there, these engineered 'CAR-Tregs' act as dedicated bodyguards for the insulin-producing cells, suppressing the autoimmune attack that would otherwise destroy them. The brilliance of the approach lies in what it avoids. Current treatments for autoimmune conditions typically suppress the entire immune system — leaving patients vulnerable to infection and long-term complications. Ferreira's CAR-Tregs don't broadly suppress immunity. They create localised protection, targeted specifically at the site of damage. Working alongside Ferreira is Dr. Holger Russ of the University of Florida, a leader in stem cell research for type 1 diabetes. Stem cells offer the possibility of an almost unlimited supply of new islet cells — enough to replenish what the immune system has destroyed. And Dr. Michael Brehm of the University of Massachusetts Medical School, who develops the humanised mouse models needed to study human immune responses to diabetes in a living system. The three pillars of the project are thus: engineer the immune system to stop attacking. Restore the lost beta cells through stem cell science. And test it all in models that faithfully mimic human disease. "These awards support the most promising work that can significantly advance the path to cures for type 1 diabetes," said Ferreira at the announcement. "This is what Breakthrough T1D believes is the next wave in type 1 diabetes therapy." There are around 8.4 million people living with type 1 diabetes worldwide. For them, the possibility of a cure that doesn't require lifelong immunosuppression — that instead recruits the immune system as an ally rather than fighting it as an enemy — is not just hopeful. It is transformative. The immune system learned to attack. Now scientists are teaching it to protect. 🩺